Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
TRAM-34 (TRAM34; TRAM 34 Triarylmethane-34) is an inhibitor of Ca2+-activated K+ channel (IKCa1, KCa3.1) with important biological activity. It inhibits Ca2+-activated K+ channel with a Kd of 20 nM, and exhibits 200- to 1500-fold higher selectivity over cloasely related ion channels..
ln Vitro |
TRAM-34 selectively blocks IKCa1 currents (Kd=25 nM), and TRAM-34 also blocks IKCa1 currents in human T84 colon epithelial cells with same efficacy (Kd= 22 nM). TRAM-34 blocks cloned and native IKCa1 channels in human T cells with a Kd of 20-25 nM and is 200 to 1500 times more selective than other ion channels. The dosage response curve demonstrates that 1 μM calcium in the pipette has a Kd of 20±3 nM and a Hill coefficient of 1.2 [1]. TRAM-34 is a selective inhibitor of KCa 3.1 channels that boosts or lowers cell proliferation depending on concentration. At intermediate concentrations (3-10 μM) TRAM-34 enhances cell proliferation, but at higher concentrations (20-100 μM) TRAM-34 lowers cell proliferation. The augmentation of cell proliferation generated by TRAM-34 was prevented by the estrogen receptor antagonists ICI182,780 and Tamoxifen. TRAM-34 also enhances progesterone receptor mRNA expression, decreases estrogen receptor-α mRNA expression, and diminishes the binding of radiolabeled estrogen to the MCF-7 estrogen receptor, in each case imitating 17β-estrogen receptor The involvement of glycol [2].
|
||
---|---|---|---|
ln Vivo |
Mice (n = 5) given a single intravenous dosage of TRAM-34 (0.5 mg/kg; 29 μM) for seven days showed no abnormalities in their clinical appearance. The TRAM-34 treatment group's body weight data (Day 1: 17.8 g; Day 7: 27.0 g) matched the vehicle-injected control mice's body weight data (Day 1: 17.4 g; Day 7: 23.4 g). Overall, at 500–1,000 times the amount required to block the channel, TRAM-34 is not acutely hazardous, according to results from these small toxicity experiments [1]. Hematoxylin and eosin (H&E) measurements of lesion area were considerably decreased with TRAM-34 treatment; the mean infarct size decreased from 22.6±3.6% in the control group (n=8) to 10 mg/kg TRAM-34. In rats treated with 40 mg/kg TRAM-34, the percentage decreased to 8.1±1.9% (n=8; P=0.004) from 11.3±2.8% in rats (n=6, mean±s.e.m., P=0.039). Additionally, this treatment helps to lessen brain shrinkage. But only the 40 mg/kg TRAM-34 group's results were statistically significant (P=0.013), but the 10 mg/kg group's results were not (P=0.11) [3].
|
||
Animal Protocol |
|
||
References |
[1]. Wulff H, et al. Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8151-6.
[2]. Roy JW, et al. The intermediate conductance Ca2+-activated K+ channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors. Br J Pharmacol. 2010 Feb 1;159(3):650-8. [3]. Chen YJ, et al. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab. 2011 Dec;31(12):2363-74 |
Molecular Formula |
C22H17CLN2
|
|
---|---|---|
Molecular Weight |
344.84
|
|
CAS # |
289905-88-0
|
|
Related CAS # |
|
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
SMILES |
ClC1=CC=CC=C1C(N2N=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (6.03 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 30% PEG400+0.5% Tween80+5% Propylene glycol : 30mg/mL Solubility in Formulation 5: 5 mg/mL (14.50 mM) in 20% SBE-β-CD in Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8999 mL | 14.4995 mL | 28.9990 mL | |
5 mM | 0.5800 mL | 2.8999 mL | 5.7998 mL | |
10 mM | 0.2900 mL | 1.4499 mL | 2.8999 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.